<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031200</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Role of fully-immersive virtual reality for paretic arm recovery in stroke rehabilitation.</ArticleTitle><Pagination><StartPage>1653749</StartPage><MedlinePgn>1653749</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1653749</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2025.1653749</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Rehabilitative training using fully immersive virtual reality (VR) has emerged as a promising method for improving motor function in patients with stroke. We evaluated the efficacy of VR technology as an adjunctive therapy in stroke rehabilitation.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A VR program was designed by the research team to facilitate the movement of the paralyzed arm, and participation was offered to inpatients on a voluntary basis at a university-affiliated Rehabilitation Medicine Center. A retrospective analysis was conducted on patients with subacute stroke who were selected without bias between November 2015 and January 2020. Clinical outcomes were compared between the VR-received (<i>n</i>&#x202f;=&#x202f;30) and the control groups (<i>n</i>&#x202f;=&#x202f;14), which received only conventional rehabilitation. Outcome measures included the Fugl-Meyer Assessment for Upper Extremity, modified Barthel Index, Functional Independence Measure, Mini-Mental Status Examination, and Motor-Free Visual Perception Test, performed before and after each treatment, and changes in the scores between the two time points were measured. A subgroup analysis was conducted according to the number of VR interventions in the VR group. Multivariate regression was used to control for confounding variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were no significant differences in baseline demographic characteristics and functional abilities between the two groups, except for a longer interval between the pre- and post-assessments in the control group (<i>p</i>&#x202f;&lt;&#x202f;0.01). The VR group showed a significantly greater improvement in Fugl-Meyer Assessment for Upper Extremity scores on the affected side than the control group did (<i>p</i>&#x202f;=&#x202f;0.01). Multivariate analysis identified VR intervention as an independent predictor of motor improvement (<i>&#x3b2;</i>&#x202f;=&#x202f;15.78), whereas delayed rehabilitation onset was negatively associated with recovery (<i>&#x3b2;</i>&#x202f;=&#x202f;-0.83).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In this case-control study, the findings suggest that incorporating fully immersive VR-based training in rehabilitation may enhance upper limb function recovery in patients with stroke in the subacute phase. Further randomized controlled studies are required to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Shin, Hwang, Kim, Park, Cho, Baik and Kim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shin</LastName><ForeName>Seyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digital Therapeutics Research Team, CHA Future Medicine Research Institute, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hwang</LastName><ForeName>Gyoseok</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yubin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>EunYoung</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Dong Rae</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baik</LastName><ForeName>Hongsuk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>MinYoung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digital Therapeutics Research Team, CHA Future Medicine Research Institute, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fugl&#x2013;Meyer assessment</Keyword><Keyword MajorTopicYN="N">activities of daily living</Keyword><Keyword MajorTopicYN="N">neuroplasticity</Keyword><Keyword MajorTopicYN="N">occupational therapy</Keyword><Keyword MajorTopicYN="N">virtual reality</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031200</ArticleId><ArticleId IdType="pmc">PMC12477025</ArticleId><ArticleId IdType="doi">10.3389/fneur.2025.1653749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shin S, Lee Y, Chang WH, Sohn MK, Lee J, Kim DY, et al. Multifaceted assessment of functional outcomes in survivors of first-time stroke. JAMA Netw Open. (2022) 5:e2233094. doi: 10.1001/jamanetworkopen.2022.33094, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.33094</ArticleId><ArticleId IdType="pmc">PMC9508656</ArticleId><ArticleId IdType="pubmed">36149652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Yang X, Sun M, He M, Sa R, Zhang K, et al. Research trends and hotspots of post-stroke upper limb dysfunction: a bibliometric and visualization analysis. Front Neurol. (2024) 15:1449729. doi: 10.3389/fneur.2024.1449729, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2024.1449729</ArticleId><ArticleId IdType="pmc">PMC11479973</ArticleId><ArticleId IdType="pubmed">39416663</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yin JH, Lee JT, Peng GS, Yang FC. Early rehabilitation after acute stroke: the golden recovery period. Acta Neurol Taiwan. (2023) 32:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34918304</ArticleId></ArticleIdList></Reference><Reference><Citation>French B, Thomas LH, Coupe J, McMahon NE, Connell L, Harrison J, et al. Repetitive task training for improving functional ability after stroke. Cochrane Database Syst Rev. (2016) 2016:CD006073. doi: 10.1002/14651858.CD006073.pub3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006073.pub3</ArticleId><ArticleId IdType="pmc">PMC6464929</ArticleId><ArticleId IdType="pubmed">27841442</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleimani M, Ghazisaeedi M, Heydari S. The efficacy of virtual reality for upper limb rehabilitation in stroke patients: a systematic review and meta-analysis. BMC Med Inform Decis Mak. (2024) 24:135. doi: 10.1186/s12911-024-02534-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-024-02534-y</ArticleId><ArticleId IdType="pmc">PMC11127427</ArticleId><ArticleId IdType="pubmed">38790042</ArticleId></ArticleIdList></Reference><Reference><Citation>Demeco A, Zola L, Frizziero A, Martini C, Palumbo A, Foresti R, et al. Immersive virtual reality in post-stroke rehabilitation: a systematic review. Sensors. (2023) 23:1712. doi: 10.3390/s23031712, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s23031712</ArticleId><ArticleId IdType="pmc">PMC9919580</ArticleId><ArticleId IdType="pubmed">36772757</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussou G, Despoti A, Patsaki I, Tzoumi D, Leventakis N, Dimitriadi N, et al. Suitability, usability and safety of fully immersive virtual reality applications for motor and cognitive rehabilitation in stroke patients preliminary data. Health Res J. (2024) 10:193&#x2013;205. doi: 10.12681/healthresj.34734</Citation><ArticleIdList><ArticleId IdType="doi">10.12681/healthresj.34734</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajjwal P, Chandrasekar KK, Battula P, Gaviria E, Awe MO, Inban P, et al. The efficacy of virtual reality-based rehabilitation in improving motor function in patients with stroke: a systematic review and meta-analysis. Ann Med Surg. (2024) 86:5425&#x2013;38. doi: 10.1097/MS9.0000000000002403, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MS9.0000000000002403</ArticleId><ArticleId IdType="pmc">PMC11374195</ArticleId><ArticleId IdType="pubmed">39238962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani Bharathi V, Manimegalai P, George ST, Pamela D, Mohammed MA, Abdulkareem KH, et al. A systematic review of techniques and clinical evidence to adopt virtual reality in post-stroke upper limb rehabilitation. Virtual Real. (2024) 28:172. doi: 10.1007/s10055-024-01065-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10055-024-01065-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiper P, Godart N, Cavalier M, Berard C, Cie&#x15b;lik B, Federico S, et al. Effects of immersive virtual reality on upper-extremity stroke rehabilitation: a systematic review with meta-analysis. J Clin Med. (2023) 13:146. doi: 10.3390/jcm13010146, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13010146</ArticleId><ArticleId IdType="pmc">PMC10780020</ArticleId><ArticleId IdType="pubmed">38202153</ArticleId></ArticleIdList></Reference><Reference><Citation>Padovani C, Pires CVG, Ferreira FPC, Borin G, Filippo TRM, Imamura M, et al. Application of the Fugl-Meyer Assessment (FMA) and the Wolf Motor Function Test (WMFT) in the recovery of upper limb function in patients after chronic stroke: a literature review. Acta Fisiatr. (2013) 20:42&#x2013;9. doi: 10.11606/issn.2317-0190.v20i1a103753</Citation><ArticleIdList><ArticleId IdType="doi">10.11606/issn.2317-0190.v20i1a103753</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Wang Z, Huang F, Su C, Du W, Jiang H, et al. A comparison of the Mini-Mental State Examination (MMSE) with the Montreal cognitive assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. (2021) 21:485. doi: 10.1186/s12888-021-03495-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-021-03495-6</ArticleId><ArticleId IdType="pmc">PMC8489046</ArticleId><ArticleId IdType="pubmed">34607584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y-C, Chang P-F, Chen Y-M, Lee Y-C, Huang S-L, Chen M-H, et al. Comparison of responsiveness of the Barthel index and modified Barthel Index in patients with stroke. Disabil Rehabil. (2023) 45:1097&#x2013;102. doi: 10.1080/09638288.2022.2055166, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2022.2055166</ArticleId><ArticleId IdType="pubmed">35357990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu E-C, Hung J-W, Yu M-Y, Chou C-X, Wu W-C, Lee Y. Practice effect and reliability of the motor-free visual perception test-4 over multiple assessments in patients with stroke. Disabil Rehabil. (2022) 44:2456&#x2013;63. doi: 10.1080/09638288.2020.1836267, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2020.1836267</ArticleId><ArticleId IdType="pubmed">33103489</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata K, Kitai T, Yoshimura Y, Honda A, Shimogai T, Otsuka S, et al. Clinical impact of functional independent measure (FIM) on 180-day readmission and mortality in elderly patients hospitalized with acute decompensated heart failure. Heart Vessel. (2021) 36:1536&#x2013;41. doi: 10.1007/s00380-021-01841-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-021-01841-y</ArticleId><ArticleId IdType="pubmed">33834270</ArticleId></ArticleIdList></Reference><Reference><Citation>Martirosov S, Bure&#x161; M, Z&#xed;tka T. Cyber sickness in low-immersive, semi-immersive, and fully immersive virtual reality. Virtual Real. (2022) 26:15&#x2013;32. doi: 10.1007/s10055-021-00507-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10055-021-00507-4</ArticleId><ArticleId IdType="pmc">PMC8132277</ArticleId><ArticleId IdType="pubmed">34025203</ArticleId></ArticleIdList></Reference><Reference><Citation>Laver KE, Lange B, George S, Deutsch JE, Saposnik G, Crotty M. Virtual reality for stroke rehabilitation. Cochrane Database Syst Rev. (2017) 11:CD008349. doi: 10.1002/14651858.CD008349.pub4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008349.pub4</ArticleId><ArticleId IdType="pmc">PMC6485957</ArticleId><ArticleId IdType="pubmed">29156493</ArticleId></ArticleIdList></Reference><Reference><Citation>Laver KE, Lange B, George S, Deutsch JE, Saposnik G, Crotty M. Virtual reality for stroke rehabilitation. Stroke. (2018) 49:e160&#x2013;1. doi: 10.1161/STROKEAHA.117.020275</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.117.020275</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;g&#xfc;n MN, Kurul R, Ya&#x15f;ar MF, Turkoglu SA, Avci &#x15e;, Yildiz N. Effect of leap motion-based 3d immersive virtual reality usage on upper extremity function in ischemic stroke patients. Arq Neuro Psiquiatr. (2019) 77:681&#x2013;8. doi: 10.1590/0004-282X20190129, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0004-282X20190129</ArticleId><ArticleId IdType="pubmed">31664343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekbib DB, Debeli DK, Zhang L, Fang S, Shao Y, Yang W, et al. A novel fully immersive virtual reality environment for upper extremity rehabilitation in patients with stroke. Ann N Y Acad Sci. (2021) 1493:75&#x2013;89. doi: 10.1111/nyas.14554, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14554</ArticleId><ArticleId IdType="pubmed">33442915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath D, Singh N, Saini M, Banduni O, Kumar N, Srivastava MVP, et al. Clinical potential and neuroplastic effect of targeted virtual reality based intervention for distal upper limb in post-stroke rehabilitation: a pilot observational study. Disabil Rehabil. (2024) 46:2640&#x2013;9. doi: 10.1080/09638288.2023.2228690</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2023.2228690</ArticleId><ArticleId IdType="pubmed">37383015</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Medina DS, Arenas-Vargas PA, Arias-Botero JC, G&#xf3;mez-V&#xe1;squez M, Jaramillo-L&#xf3;pez MF, Gaspar-Toro JM. New approaches to recovery after stroke. Neurol Sci. (2024) 45:55&#x2013;63. doi: 10.1007/s10072-023-07012-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-023-07012-3</ArticleId><ArticleId IdType="pmc">PMC10761524</ArticleId><ArticleId IdType="pubmed">37697027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Wang H, Wang H, Qie S. Impact of the combination of virtual reality and noninvasive brain stimulation on the upper limb motor function of stroke patients: a systematic review and meta-analysis. J Neuroeng Rehabil. (2024) 21:179. doi: 10.1186/s12984-024-01474-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12984-024-01474-y</ArticleId><ArticleId IdType="pmc">PMC11453052</ArticleId><ArticleId IdType="pubmed">39369259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceradini M, Losanno E, Micera S, Bandini A, Orlandi S. Immersive VR for upper-extremity rehabilitation in patients with neurological disorders: a scoping review. J Neuroeng Rehabil. (2024) 21:75. doi: 10.1186/s12984-024-01367-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12984-024-01367-0</ArticleId><ArticleId IdType="pmc">PMC11088157</ArticleId><ArticleId IdType="pubmed">38734690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031195</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Early acupuncture intervention strongly associates with improved swallowing recovery in post-stroke dysphagia: a multicenter real-world cohort study.</ArticleTitle><Pagination><StartPage>1553947</StartPage><MedlinePgn>1553947</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1553947</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2025.1553947</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Post-Stroke Dysphagia (PSD) is a common complication of stroke, significantly impairing recovery and quality of life. Acupuncture has shown potential in improving swallowing function, yet the optimal timing of intervention remains unclear. This study evaluated the effect of acupuncture timing on swallowing recovery in stroke patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a multicenter real-world study across 27 hospitals in China, enrolling 382 stroke patients with PSD. Inclusion required symptom onset within 90&#x202f;days and a Water Swallowing Test (WST) score &gt; 2. The primary outcome was swallowing function recovery at discharge, 90&#x202f;&#xb1;&#x202f;7&#x202f;days, and 180&#x202f;&#xb1;&#x202f;7&#x202f;days post-onset. Multivariate logistic regression was used to adjust for potential confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 359 participants with complete data, early acupuncture (0-14&#x202f;days post-stroke) was strongly associated with improved swallowing recovery. Delayed treatment beyond 28&#x202f;days significantly reduced recovery odds at discharge (adjusted OR&#x202f;=&#x202f;2.17; 95% CI: 1.12-4.21) and 90&#x202f;days (adjusted OR&#x202f;=&#x202f;2.57; 95% CI: 1.31-5.04). This effect diminished at 180&#x202f;days (adjusted OR&#x202f;=&#x202f;1.55; 95% CI: 0.52-4.61). Medullary lesions and diabetes were also associated with poorer outcomes, while hyperlipidemia showed a potential protective effect. The study relied on WST as the sole functional assessment, which, while practical, lacks the sensitivity of instrumental measures like VFSS or FEES for detecting silent aspiration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Early acupuncture intervention within 2 weeks post-stroke is strongly associated with improved swallowing recovery in real-world clinical practice. Delayed treatment may limit clinical benefit. Future research should incorporate instrumental swallowing assessments and randomized trials to refine acupuncture timing and validate these findings.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ChiCTR2100042721.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Li, Li, Wang, Li, Wang, Yang, Shen, Yang, Xu, Xu, Lu, Wang, Wang, Zhou, Li, Peng, Cao, Chen, Zheng and Han.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Junlong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guiping</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Cerebropathy Acupuncture Therapy of State Administration of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Sha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhijie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Mengnan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing University of Chinese Medicine Dongzhimen Hospital Medical in Xiamen, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhiliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jiangsu Second Hospital of Traditional Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yongjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiangfang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Tianjin Wuqing Traditional Chinese Medicine Hospital Affiliated to Tianjin University of Traditional Chinese Medicine, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaoshan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Chifeng Municipal Hospital, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acupuncture</Keyword><Keyword MajorTopicYN="N">post-stroke dysphagia</Keyword><Keyword MajorTopicYN="N">real-world study</Keyword><Keyword MajorTopicYN="N">swallowing function</Keyword><Keyword MajorTopicYN="N">timing</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031195</ArticleId><ArticleId IdType="pmc">PMC12477722</ArticleId><ArticleId IdType="doi">10.3389/fneur.2025.1553947</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. (2005) 36:2756&#x2013;63. doi: 10.1161/01.STR.0000190056.76543.eb</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000190056.76543.eb</ArticleId><ArticleId IdType="pubmed">16269630</ArticleId></ArticleIdList></Reference><Reference><Citation>Labeit B, Michou E, Hamdy S, Trapl-Grundschober M, Suntrup-Krueger S, Muhle P, et al. The assessment of dysphagia after stroke: state of the art and future directions. Lancet Neurol. (2023) 22:858&#x2013;70. doi: 10.1016/S1474-4422(23)00153-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(23)00153-9</ArticleId><ArticleId IdType="pubmed">37596008</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnecke T, Labeit B, Schroeder J, Reckels A, Ahring S, Lapa S, et al. Neurogenic dysphagia: systematic review and proposal of a classification system. Neurology. (2021) 96:e876&#x2013;89. doi: 10.1212/WNL.0000000000011350, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011350</ArticleId><ArticleId IdType="pubmed">33318164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertscher B, Speyer R, Palmieri M, Plant C. Bedside screening to detect oropharyngeal dysphagia in patients with neurological disorders: an updated systematic review. Dysphagia. (2014) 29:204&#x2013;12. doi: 10.1007/s00455-013-9490-9 10.1007/s00455, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-013-9490-9</ArticleId><ArticleId IdType="pubmed">24026520</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels SK, Anderson JA, Willson PC. Valid items for screening dysphagia risk in patients with stroke: a systematic review. Stroke. (2012) 43:892&#x2013;7. doi: 10.1161/STROKEAHA.111.640946, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.640946</ArticleId><ArticleId IdType="pubmed">22308250</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Saver JL, Alexander DN, Furie KL, Hopkins LN, Katzan IL, et al. Clinical performance measures for adults hospitalized with acute ischemic stroke: performance measures for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2014) 45:3472&#x2013;98. doi: 10.1161/STR.0000000000000045, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0000000000000045</ArticleId><ArticleId IdType="pubmed">25256184</ArticleId></ArticleIdList></Reference><Reference><Citation>Luker JA, Wall K, Bernhardt J, Edwards I, Grimmer-Somers K. Measuring the quality of dysphagia management practices following stroke: a systematic review. Int J Stroke. (2010) 5:466&#x2013;76. doi: 10.1111/j.1747-4949.2010.00488.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-4949.2010.00488.x</ArticleId><ArticleId IdType="pubmed">21050403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray BD, Smith CJ, Cloud GC, Enderby P, James M, Paley L, et al. The association between delays in screening for and assessing dysphagia after acute stroke, and the risk of stroke-associated pneumonia. J Neurol Neurosurg Psychiatry. (2017) 88:25&#x2013;30. doi: 10.1136/jnnp-2016-313356, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313356</ArticleId><ArticleId IdType="pubmed">27298147</ArticleId></ArticleIdList></Reference><Reference><Citation>Boaden E, Burnell J, Hives L, Dey P, Clegg A, Lyons MW, et al. Screening for aspiration risk associated with dysphagia in acute stroke. Cochrane Database Syst Rev. (2021) 10:CD012679. doi: 10.1002/14651858.CD012679.pub2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012679.pub2</ArticleId><ArticleId IdType="pmc">PMC8521523</ArticleId><ArticleId IdType="pubmed">34661279</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Zhang Z, Zhao Y, Liu J, Qiu J, Gong Y, et al. The impact of acupuncture on neuroplasticity after ischemic stroke: a literature review and perspectives. Front Cell Neurosci. (2022) 16:817732. doi: 10.3389/fncel.2022.817732, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.817732</ArticleId><ArticleId IdType="pmc">PMC9685811</ArticleId><ArticleId IdType="pubmed">36439200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zhang XG, Zhong LL, Zhong LLD, Chen Z-x, Li Y, et al. Acupuncture for neurogenesis in experimental ischemic stroke: a systematic review and meta-analysis. Sci Rep. (2016) 6:19521. doi: 10.1038/srep19521, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19521</ArticleId><ArticleId IdType="pmc">PMC4726177</ArticleId><ArticleId IdType="pubmed">26786869</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Xu H, Liu B. Real world research: a complementary method to establish the effectiveness of acupuncture. BMC Complement Altern Med. (2015) 15:153. doi: 10.1186/s12906-015-0676-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12906-015-0676-6</ArticleId><ArticleId IdType="pmc">PMC4440554</ArticleId><ArticleId IdType="pubmed">25997850</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Zhang K, Li Y, Chen L, Gao H, Chen H. Real-world evidence of traditional Chinese medicine treatment on cancer: a literature-based review. Evid Based Complement Alternat Med. (2022) 2022:7770380. doi: 10.1155/2022/7770380</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7770380</ArticleId><ArticleId IdType="pmc">PMC9259235</ArticleId><ArticleId IdType="pubmed">35815277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai ST, Tseng CH, Lin MC, Liao HY, Teoh BK, San S, et al. Acupuncture reduced the medical expenditure in migraine patients: real-world data of a 10-year national cohort study. Medicine. (2020) 99:e21345. doi: 10.1097/MD.0000000000021345, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000021345</ArticleId><ArticleId IdType="pmc">PMC7593014</ArticleId><ArticleId IdType="pubmed">32769867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui M, Xue L, Ying X. Association of acupuncture treatment with mortality of type 2 diabetes in China: evidence of a real-world study. Int J Environ Res Public Health. (2020) 17:7801., PMID:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7663761</ArticleId><ArticleId IdType="pubmed">33113774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YQ, Jing X, Guyatt G. Improving acupuncture research: progress, guidance, and future directions. BMJ. (2022) 376:o487. doi: 10.1136/bmj.o487, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o487</ArticleId><ArticleId IdType="pubmed">35217523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Liu J, Cui J, et al. Association of acupuncture treatment with mortality of type 2 diabetes in China: evidence of a real-world study. J Integr Med. (2020) 17:7801. doi: 10.3390/ijerph17217801</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17217801</ArticleId><ArticleId IdType="pmc">PMC7663761</ArticleId><ArticleId IdType="pubmed">33113774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YJ, Wang SS, Zhao XQ, et al. Experts Group for the Chinese Dysphagia and Nutrition Management Manual for Acute Stroke Patients, Chinese Stroke Association, China National Clinical Research Center for Neurological Diseases. (2019) 14:1153&#x2013;69. doi: 10.3969/j.issn.1673-5765.2019.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1673-5765.2019.11.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Society of Neurology Neurological Rehabilitation Committee Stroke Committee of the Chinese Society of Neurology . Guidelines for early rehabilitation treatment of stroke in China. Chin J Neurol. (2017) 50:405&#x2013;12. doi: 10.3760/cma.j.issn.1006-7876.2017.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1006-7876.2017.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziewas R, Michou E, Trapl GM, Lal A, Arsava EM, Bath PM, et al. European stroke organisation and European Society for Swallowing Disorders guideline for the diagnosis and treatment of post-stroke dysphagia. Eur Stroke J. (2021) 6:LXXXIX&#x2013;CXV. doi: 10.1177/23969873211039721</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23969873211039721</ArticleId><ArticleId IdType="pmc">PMC8564153</ArticleId><ArticleId IdType="pubmed">34746431</ArticleId></ArticleIdList></Reference><Reference><Citation>T/CACM 1316-2019 . Clinical guidelines for diagnosis and treatment of internal diseases in TCM post-stroke dysphagia. Beijing, China: China Academy of Chinese Medical Sciences; (2019).</Citation></Reference><Reference><Citation>World Federation of Chinese Medicine Societies . International standardized manipulations of Chinese medicine Xingnao Kaiqiao acupuncture for stroke (T/WFCMS SCM69-2021). Beijing, China: China Medical Science Press; (2021).</Citation></Reference><Reference><Citation>Tian ZY, Liao X, Gao Y, Liang SB, Zhang CY, Xu DH, et al. An overview of systematic reviews and meta-analyses on acupuncture for post-acute stroke dysphagia. Geriatrics. (2019) 4:68. doi: 10.3390/geriatrics4040068, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/geriatrics4040068</ArticleId><ArticleId IdType="pmc">PMC6960703</ArticleId><ArticleId IdType="pubmed">31817993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Ma X, Huang J, Li J, Ma L, Xu D, et al. Effect of acupuncture treatment on dysphagia caused by pseudobulbar paralysis after stroke: a systematic review and meta-analysis. Ann Palliat Med. (2022) 11:2257&#x2013;64. doi: 10.21037/apm-21-3551</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-3551</ArticleId><ArticleId IdType="pubmed">35400158</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Cui Y, Zhao Y, Jiao H. Bibliometric analysis: research trends and performances of stroke on acupuncture. J Pain Res. (2024) 17:1837&#x2013;51. doi: 10.2147/JPR.S449619, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JPR.S449619</ArticleId><ArticleId IdType="pmc">PMC11128237</ArticleId><ArticleId IdType="pubmed">38799275</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, Gang WJ, Xiu WC, Tian ZY, Hu XY, Jiao RM, et al. Analysis on influencing factors of acupuncture curative effect based on experts' experience. Zhongguo Zhen Jiu. (2022) 42:585&#x2013;9. doi: 10.13703/j.0255-2930.20210330-k0002</Citation><ArticleIdList><ArticleId IdType="doi">10.13703/j.0255-2930.20210330-k0002</ArticleId><ArticleId IdType="pubmed">35543954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, Ding Y, Han Z, Duan H, Geng X. Optimal rehabilitation strategies for early postacute stroke recovery: an ongoing inquiry. Brain Circ. (2023) 9:201&#x2013;4. doi: 10.4103/bc.bc_33_23, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/bc.bc_33_23</ArticleId><ArticleId IdType="pmc">PMC10821682</ArticleId><ArticleId IdType="pubmed">38284113</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Peng X, Dahmani L, Wang H, Zhang M, Shan Y, et al. Patterns of motor recovery and structural neuroplasticity after basal ganglia infarcts. Neurology. (2020) 95:e1174&#x2013;87. doi: 10.1212/WNL.0000000000010149, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010149</ArticleId><ArticleId IdType="pmc">PMC7538227</ArticleId><ArticleId IdType="pubmed">32586896</ArticleId></ArticleIdList></Reference><Reference><Citation>Jharbade M, Ramachandran S, V S, Solomon MJ. Functional training for lower extremities in stroke survivors: a scoping review. Cureus. (2024) 16:e58087. doi: 10.7759/cureus.58087</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.58087</ArticleId><ArticleId IdType="pmc">PMC11088721</ArticleId><ArticleId IdType="pubmed">38738032</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke. (2000) 31:1429&#x2013;38. doi: 10.1161/01.STR.31.6.1429, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.31.6.1429</ArticleId><ArticleId IdType="pubmed">10835468</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Pei J, Fu QH, Wang L-Y, Zhan Y-J, Tao L. Earlier acupuncture enhancing long-term effects on motor dysfunction in acute ischemic stroke: retrospective cohort study. Am J Chin Med. (2020) 48:1787&#x2013;802. doi: 10.1142/S0192415X20500895, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/S0192415X20500895</ArticleId><ArticleId IdType="pubmed">33308097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Ding Y, Peng M, Wang X, Li Y, Cheng X. Influence of acupuncture and other clinical factors on the recovery of limb motor function in patients after stroke: a retrospective study. J Multidiscip Healthc. (2023) 16:463&#x2013;74. doi: 10.2147/JMDH.S398202, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S398202</ArticleId><ArticleId IdType="pmc">PMC9961212</ArticleId><ArticleId IdType="pubmed">36852335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Chi X, Lyu J, Xu Z, Fu G, Liu Y, et al. An overview of the evidence to guide decision-making in acupuncture therapies for early recovery after acute ischemic stroke. Front Neurol. (2022) 13:1005819. doi: 10.3389/fneur.2022.1005819, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.1005819</ArticleId><ArticleId IdType="pmc">PMC9608668</ArticleId><ArticleId IdType="pubmed">36313493</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Netto P, Rumbach A, Dunn K, Finch E. Clinical predictors of dysphagia recovery after stroke: a systematic review. Dysphagia. (2023) 38:1&#x2013;22. doi: 10.1007/s00455-022-10443-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-022-10443-3</ArticleId><ArticleId IdType="pmc">PMC9873776</ArticleId><ArticleId IdType="pubmed">35445366</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CA, Colletti CM, Ding MC. Post-stroke dysphagia: recent insights and unanswered questions. Curr Neurol Neurosci Rep. (2020) 20:61. doi: 10.1007/s11910-020-01081-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-020-01081-z</ArticleId><ArticleId IdType="pmc">PMC7604228</ArticleId><ArticleId IdType="pubmed">33136216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmskoetter J, Bonilha L, Martin-Harris B, Elm JJ, Horn J, Bonilha HS. Factors influencing oral intake improvement and feeding tube dependency in patients with poststroke dysphagia. J Stroke Cerebrovasc Dis. (2019) 28:1421&#x2013;30. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.031, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2019.03.031</ArticleId><ArticleId IdType="pmc">PMC6691972</ArticleId><ArticleId IdType="pubmed">30962081</ArticleId></ArticleIdList></Reference><Reference><Citation>Smithard DG. Dysphagia management and stroke units. Curr Phys Med Rehabil Rep. (2016) 4:287&#x2013;94. doi: 10.1007/s40141-016-0129-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40141-016-0129-6</ArticleId><ArticleId IdType="pmc">PMC5148787</ArticleId><ArticleId IdType="pubmed">28018754</ArticleId></ArticleIdList></Reference><Reference><Citation>Konak HE, Alemdaro&#x11f;lu E, Alta&#x15f; EU. The relationship between dysphagia and the localisation of brain lesion in stroke: is the involvement of the pons and medulla important? Somatosens Mot Res. (2024) 41:34&#x2013;41. doi: 10.1080/08990220.2023.2165058, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08990220.2023.2165058</ArticleId><ArticleId IdType="pubmed">36625230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Sanossian N, Starkman S, Avila-Rinek G, Eckstein M, Sharma LK, et al. Adiposity and outcome after ischemic stroke: obesity paradox for mortality and obesity parabola for favorable functional outcomes. Stroke. (2021) 52:144&#x2013;51. doi: 10.1161/STROKEAHA.119.027900, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.119.027900</ArticleId><ArticleId IdType="pubmed">33272129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka S, Wakabayashi H, Yoshida T, Mori N, Watanabe R, Nishioka E. Obese Japanese patients with stroke have higher functional recovery in convalescent rehabilitation wards: a retrospective cohort study. J Stroke Cerebrovasc Dis. (2016) 25:26&#x2013;33. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.029, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2015.08.029</ArticleId><ArticleId IdType="pubmed">26403365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Yan XL, Qu Y, Guo ZN, Yang Y. Association between abnormal body weight and stroke outcome: a meta-analysis and systematic review. Eur J Neurol. (2021) 28:2552&#x2013;64. doi: 10.1111/ene.14881, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14881</ArticleId><ArticleId IdType="pubmed">33896081</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland SA, Wellwood I, Kuys S. Effect of abnormal body weight on mortality and functional recovery in adults after stroke: an umbrella review. Int J Stroke. (2024) 19:397&#x2013;405. doi: 10.1177/17474930231212972, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17474930231212972</ArticleId><ArticleId IdType="pubmed">37897100</ArticleId></ArticleIdList></Reference><Reference><Citation>Morone G, Iosa M, Paolucci T, Muzzioli L, Paolucci S. Relationship between body mass index and rehabilitation outcomes in subacute stroke with dysphagia. Am J Phys Med Rehabil. (2019) 98:608&#x2013;12. doi: 10.1097/PHM.0000000000001159, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001159</ArticleId><ArticleId IdType="pubmed">30768452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031153</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study).</ArticleTitle><Pagination><StartPage>1565094</StartPage><MedlinePgn>1565094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1565094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1565094</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Patients receiving anticoagulation for atrial fibrillation (AF) are required to consult their doctor before starting Ramadan fasting to get their authorization for fasting and adapt their treatment. More often, a once-daily regimen is proposed to facilitate their intake schedule. Apixaban, a direct oral anticoagulant, prescribed twice daily with an optimal benefit/risk ratio in numerous situations, has very limited data regarding its use during Ramadan.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The aim of this study was to evaluate the safety and the efficacy of apixaban for stroke prevention in AF patients during the month of Ramadan.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">An observational, multicentric study was performed in Tunisia during two consecutive years during the specific month of Ramadan. The API-RAM study included AF patients who were on apixaban and fasted at least 10&#xa0;days. Efficacy was defined by the absence of ischemic events, and safety was established by classifying bleeding events using the BARC (Bleeding Academic Research Consortium) classification during the study period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 257 patients were included in our study. No ischemic events were reported during the study period. Minor bleeding events were reported in only 12 patients (4.7%), with no major bleeding event. Based on multivariate analysis, independent predictors for the bleeding risk of our population were as follows: smoking, history of hypertension, and creatinine clearance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Apixaban seems to be safe and effective for the prevention of the thromboembolic episode in AF patients during Ramadan fasting. Larger studies such as randomized clinical trials are necessary to confirm these results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Ghrab, Gargouri, Addad, Cheikhrouhou, Jabeur, Charfeddine, Bahloul, Triki, Ellouze, Abidi, Mallek, Triki, Abdessalem, Elalamy and Abid.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghrab</LastName><ForeName>Aiman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargouri</LastName><ForeName>Rania</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addad</LastName><ForeName>Faouzi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheikhrouhou</LastName><ForeName>Anis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabeur</LastName><ForeName>Mariem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charfeddine</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahloul</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Zied</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellouze</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abidi</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallek</LastName><ForeName>Souad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Faten</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdessalem</LastName><ForeName>Salem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic Pasteur Tunis, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elalamy</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Department, American Hospital of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondation UPM des Sciences de la Sant&#xe9;, Marrakesh, Morocco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abid</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ramadan</Keyword><Keyword MajorTopicYN="N">anticoagulants</Keyword><Keyword MajorTopicYN="N">apixaban</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">fasting</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031153</ArticleId><ArticleId IdType="pmc">PMC12476992</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1565094</ArticleId><ArticleId IdType="pii">1565094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addad F., Amami M., Ibn Elhadj Z., Chakroun T., Marrakchi S., Kachboura S. (2014). Does ramadan fasting affect the intensity of acenocoumarol-induced anticoagulant effect? Br. J. Haematol. 166 (5), 792&#x2013;794. 10.1111/bjh.12897</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12897</ArticleId><ArticleId IdType="pubmed">24749553</ArticleId></ArticleIdList></Reference><Reference><Citation>
Agrawal A., Kerndt C. C., Manna B. (2024). &#x201c;Apixaban,&#x201d; in 
<i>StatPearls. Treasure Island</i>
, FL: StatPearls Publishing. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK507910/(Accessed: January 4, 2025).</Citation></Reference><Reference><Citation>Akhtar A. M., Ghouri N., Chahal C. A. A., Patel R., Ricci F., Sattar N., et al. (2022). Ramadan fasting: recommendations for patients with cardiovascular disease. Heart 108 (4), 258&#x2013;265. 10.1136/heartjnl-2021-319273</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319273</ArticleId><ArticleId IdType="pmc">PMC8819657</ArticleId><ArticleId IdType="pubmed">33990414</ArticleId></ArticleIdList></Reference><Reference><Citation>AlAyoubi F. (2021). The effect of ramadan fasting on oral anticoagulant: experience of tertiary academic hospital. Ann. Rev. and Res. 6 (3). 10.19080/ARR.2021.06.555688</Citation><ArticleIdList><ArticleId IdType="doi">10.19080/ARR.2021.06.555688</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ghumlas A. K. (2024). Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case&#x2013;control study. Sci. Rep. 14 (1), 13855. 10.1038/s41598-024-64582-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-64582-8</ArticleId><ArticleId IdType="pmc">PMC11180170</ArticleId><ArticleId IdType="pubmed">38879576</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulhem M., Susarla R., Alabdulaali L., Khunti K., Karamat M. A., Rasiah T., et al. (2020). The effect of ramadan fasting on cardiovascular events and risk factors in patients with type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 159, 107918. 10.1016/j.diabres.2019.107918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2019.107918</ArticleId><ArticleId IdType="pubmed">31711857</ArticleId></ArticleIdList></Reference><Reference><Citation>AlShoaibi N., Al Harbi M., Modaimegh H., Al Qubbany A., Al Saif S., Connolly D. L., et al. (2021). Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: perspectives on improving patient care. Expert Rev. Cardiovasc. Ther. 19 (3), 221&#x2013;236. 10.1080/14779072.2021.1878878</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14779072.2021.1878878</ArticleId><ArticleId IdType="pubmed">33475462</ArticleId></ArticleIdList></Reference><Reference><Citation>Anghel L. A., Farcas A. M., Oprean R. N. (2019). An overview of the common methods used to measure treatment adherence. Med. Pharm. Rep. 92 (2), 117&#x2013;122. 10.15386/mpr-1201</Citation><ArticleIdList><ArticleId IdType="doi">10.15386/mpr-1201</ArticleId><ArticleId IdType="pmc">PMC6510353</ArticleId><ArticleId IdType="pubmed">31086837</ArticleId></ArticleIdList></Reference><Reference><Citation>Batarfi A., Alenezi H., Alshehri A., Balelah S., Kazim H., Algthami M., et al. (2021). Patient-guided modifications of oral anticoagulant drug intake during ramadan fasting: a multicenter cross-sectional study. J. Thrombosis Thrombolysis 51 (2), 485&#x2013;493. 10.1007/s11239-020-02218-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02218-0</ArticleId><ArticleId IdType="pmc">PMC7886720</ArticleId><ArticleId IdType="pubmed">32666427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortman L. V., Mitchell F., Naveiro S., P&#xe9;rez Morales J., Gonzalez C. D., Di Girolamo G., et al. (2023). Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J. Clin. Pharmacol. 63 (4), 383&#x2013;396. 10.1002/jcph.2184</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2184</ArticleId><ArticleId IdType="pubmed">36433678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajos G., Konieczynska M., Zalewski J., Undas A. (2015). Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc. Diabetol. 14, 44. 10.1186/s12933-015-0207-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-015-0207-2</ArticleId><ArticleId IdType="pmc">PMC4432887</ArticleId><ArticleId IdType="pubmed">25928628</ArticleId></ArticleIdList></Reference><Reference><Citation>
Granger C. B., Alexander J. H., McMurray J. J. V., Lopes R. D., Hylek E. M., Hanna M., et al.  (2011). Apixaban <i>versus</i> warfarin in patients with atrial fibrillation. N. Engl. J. Med.
365 (11), 981&#x2013;992. 10.1056/NEJMoa1107039

</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Harskamp R. E., Lucassen W. A. M., Lopes R. D., Himmelreich J. C. L., Parati G., Weert H. C. P. M. v. (2022). Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 77 (3), 191&#x2013;195. 10.1080/00015385.2021.1882111</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00015385.2021.1882111</ArticleId><ArticleId IdType="pubmed">33685380</ArticleId></ArticleIdList></Reference><Reference><Citation>Katada Y., Nakagawa S., Nishimura A., Sato Y. K., Taue H., Matsumura K., et al. (2019). Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery. Eur. J. Clin. Pharmacol. 75 (4), 561&#x2013;568. 10.1007/s00228-018-2592-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-018-2592-4</ArticleId><ArticleId IdType="pubmed">30460405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B. H., Joo Y., Kim M. S., Choe H. K., Tong Q., Kwon O. (2021). Effects of intermittent fasting on the circulating levels and circadian rhythms of hormones. Endocrinol. Metabolism 36 (4), 745&#x2013;756. 10.3803/EnM.2021.405</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2021.405</ArticleId><ArticleId IdType="pmc">PMC8419605</ArticleId><ArticleId IdType="pubmed">34474513</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsted A., Nordestgaard B. G. (2018). Smoking is associated with increased risk of major bleeding: a prospective cohort study. Thrombosis Haemostasis 119, 39&#x2013;47. 10.1055/s-0038-1675798</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1675798</ArticleId><ArticleId IdType="pubmed">30597498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R., Rao S. V., Bhatt D. L., Gibson C. M., Caixeta A., Eikelboom J., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (23), 2736&#x2013;2747. 10.1161/CIRCULATIONAHA.110.009449</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.009449</ArticleId><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirghani H. O., Faisal A. F. F., Salman A. W., Hussain G. A., Abdulaziz A. E., Muflih A. M., et al. (2023). Adherence to antidiabetic medication during the month of ramadan among diabetes mellitus patients in the Kingdom of Saudi Arabia. J. Adv. Zoology 44 (5), 747&#x2013;755. 10.53555/jaz.v44i5.3110</Citation><ArticleIdList><ArticleId IdType="doi">10.53555/jaz.v44i5.3110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali S., Ben Halima A., Chabrak S., Chettaoui R., Ben Halima M., Haggui A., et al. (2021). Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: results from the national Tunisian registry of atrial fibrillation (NATURE&#x2010;AF). Clin. Cardiol. 44 (4), 501&#x2013;510. 10.1002/clc.23558</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23558</ArticleId><ArticleId IdType="pmc">PMC8027580</ArticleId><ArticleId IdType="pubmed">33704830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;aloza-Mart&#xed;nez E., Moreno G., Aroca-Crevill&#xe9;n A., Huertas S., Vicent L., Rosillo N., et al. (2022). Circadian rhythms in thrombosis and atherothrombotic events. Front. Bioscience-Landmark 27 (2), 51. 10.31083/j.fbl2702051</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbl2702051</ArticleId><ArticleId IdType="pubmed">35226994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad M. S. (2023). Ramadan fasting as a goal-pursuit: why people fast, and how motives affect their experience. Motivation Sci. 9, 327&#x2013;339. 10.1037/mot0000310</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/mot0000310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosca C. I., Sharma A., Nisulescu D. D., Otiman G., Duda-Seiman D. M., Morariu S. I., et al. (2023). Prevalence of cardio-embolic brain complications in permanent and paroxysmal atrial fibrillation patients. Healthcare 11 (2), 175. 10.3390/healthcare11020175</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11020175</ArticleId><ArticleId IdType="pmc">PMC9858915</ArticleId><ArticleId IdType="pubmed">36673543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandrini L., Ieraci A., Amadio P., Zar&#xe0; M., Barbieri S. S. (2020). Impact of acute and chronic stress on thrombosis in healthy individuals and cardiovascular disease patients. Int. J. Mol. Sci. 21 (21), 7818. 10.3390/ijms21217818</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21217818</ArticleId><ArticleId IdType="pmc">PMC7659944</ArticleId><ArticleId IdType="pubmed">33105629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoeb M., Fang M. C. (2013). Assessing bleeding risk in patients taking anticoagulants. J. thrombosis thrombolysis 35 (3), 312&#x2013;319. 10.1007/s11239-013-0899-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-013-0899-7</ArticleId><ArticleId IdType="pmc">PMC3888359</ArticleId><ArticleId IdType="pubmed">23479259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan K., Al Banna R., Qader A. M., Husain A. (2021). Does fasting during ramadan influence the therapeutic effect of warfarin? J. Clin. Pharm. Ther. 46 (1), 86&#x2013;92. 10.1111/jcpt.13254</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13254</ArticleId><ArticleId IdType="pubmed">32926452</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabelsi K., Ammar A., Boujelbane M. A., Puce L., Garbarino S., Scoditti E., et al. (2022). Religious fasting and its impacts on individual, public, and planetary health: fasting as a &#x201c;religious health asset&#x201d; for a healthier, more equitable, and sustainable society. Front. Nutr. 9, 1036496. 10.3389/fnut.2022.1036496</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.1036496</ArticleId><ArticleId IdType="pmc">PMC9729557</ArticleId><ArticleId IdType="pubmed">36505246</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijens B., Heidbuchel H. (2015). Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. EP Eur. 17 (4), 514&#x2013;523. 10.1093/europace/euu311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu311</ArticleId><ArticleId IdType="pubmed">25694538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Chang A. R., Inker L. A., McAdams-DeMarco M., Grams M. E., Shin J. I. (2023). Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation 148 (19), 1445&#x2013;1454. 10.1161/CIRCULATIONAHA.123.065614</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.065614</ArticleId><ArticleId IdType="pmc">PMC10840683</ArticleId><ArticleId IdType="pubmed">37681341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz T. (2023). Evaluation of medication adherence of individuals with chronic diseases during ramadan. Ankara Med. J. 23 (3), 344&#x2013;356. 10.5505/amj.2023.70842</Citation><ArticleIdList><ArticleId IdType="doi">10.5505/amj.2023.70842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zghal Mghaieth F., Bonkano A., Boudiche S., Ayari J., Ben Mansour N., Rekik B., et al. (2019). Oral anticoagulation therapy using acenocoumarol during the month of ramadan: a comparative study between fasting and non-fasting patients. La Tunis. Medicale 97 (10), 1177&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41029853</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>370</StartPage><MedlinePgn>370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-025-02900-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Combination therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose co-transporter 2 inhibitors (SGLT2i), and/or finerenone offers a strategy to reduce the risk of adverse cardiovascular and renal outcomes. This study aimed to quantify the cardiorenal benefits of combination regimens with GLP-1RA, SGLT2i, and/or finerenone versus corresponding monotherapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE and Embase were systematically searched, yielding four post hoc analyses of randomized controlled trials (RCTs) and ten observational studies that met prespecified inclusion criteria. Among RCTs, a random-effects meta-regression was performed to assess whether the effect of GLP-1RAs on cardiorenal outcomes differed based on baseline SGLT2i use. Additionally, for observational studies, random-effects meta-analyses were performed to estimate the effect of combination therapy versus monotherapy on the risk of cardiorenal outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Across RCTs, p for interaction was&#x2009;&gt;&#x2009;0.05 for major adverse cardiac events (MACE) (p&#x2009;=&#x2009;0.730), cardiovascular (CV) mortality (p&#x2009;=&#x2009;0.889), non-fatal myocardial infarction (MI) (p&#x2009;=&#x2009;0.237), non-fatal stroke (p&#x2009;=&#x2009;0.696), all-cause mortality (p&#x2009;=&#x2009;0.682), heart failure (HF) hospitalization (p&#x2009;=&#x2009;0.257), and renal composite outcome (p&#x2009;=&#x2009;0.890), supporting that GLP-1RAs result in a consistent reduction in outcomes irrespective of baseline SGLT2i use. In observational trials, compared to SGLT2i monotherapy, GLP-1RA and SGLT2i combination therapy significantly reduced MACE (HR 0.59, 95% CI 0.47-0.75), MI (HR 0.73, 95% CI 0.61-0.88), stroke (HR 0.72, 95% CI 0.53-0.97), all-cause mortality (HR 0.57, 95% CI 0.48-0.67), and HF hospitalization/events (HR 0.71, 95% CI 0.59-0.86). Compared to GLP-1RA monotherapy, SGLT2i and GLP-1RA combination therapy significantly reduced CV mortality (HR 0.35, 95% CI 0.15-0.81), MI (HR 0.93, 95% CI 0.88-0.97), stroke (HR 0.92, 95% CI 0.88-0.96), all-cause mortality (HR 0.59, 95% 0.49-0.70), HF hospitalization/events (HR 0.84, 95% CI 0.81-0.88), and serious renal events (HR 0.43, 95% CI 0.23-0.80). Compared to either SGLT2i or finerenone monotherapy, SGLT2i and finerenone combination therapy significantly reduced all-cause mortality and major adverse kidney events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combination therapy with GLP-1RA, SGLT2i, or finerenone confers cardiorenal protection beyond monotherapy in T2D, as supported by concordant evidence from RCTs and large real-world cohorts. These findings support broader clinical adoption of dual-agent strategies but also underscore the need for dedicated prospective trials powered to assess hard clinical outcomes with dual-agent strategies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shokravi</LastName><ForeName>Arveen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. shokravi@student.ubc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seth</LastName><ForeName>Jayant</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>G B John</ForeName><Initials>GBJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Cardiovascular Innovation, Dilwari Cardiovascular Institute, Division of Cardiology, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054795">Incretins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C576501">finerenone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593833">GLP1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009287">Naphthyridines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="Y">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054795" MajorTopicYN="Y">Incretins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="Y">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N" AutoHM="Y">Glucagon-Like Peptide-1 Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009287" MajorTopicYN="N" AutoHM="Y">Naphthyridines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiometabolic risk</Keyword><Keyword MajorTopicYN="N">Cardiovascular outcomes</Keyword><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Finerenone</Keyword><Keyword MajorTopicYN="N">GLP-1 receptor agonist</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Renal outcomes</Keyword><Keyword MajorTopicYN="N">SGLT2 inhibitor</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. This study is a meta-analysis and did not involve direct recruitment of human participants. Competing interests: Arveen Shokravi, and Jayant Seth, have no conflicts of interest to declare. G.B. John Mancini reports receiving honoraria from Eli Lilly, Boehringer Ingelheim, Novo Nordisk, GlaxoSmithKline, and Bayer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>1</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41029853</ArticleId><ArticleId IdType="doi">10.1186/s12933-025-02900-8</ArticleId><ArticleId IdType="pii">10.1186/s12933-025-02900-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang H, Zhou XD, Shapiro MD, et al. Global burden of metabolic diseases, 1990&#x2013;2021. Metabolism. 2024;160: 155999. https://doi.org/10.1016/j.metabol.2024.155999 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2024.155999</ArticleId><ArticleId IdType="pubmed">39151887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu XY, Shi MQ, Jiang ZM, Xiao-Li, Tian JW, Su FF. Global, regional, and national burden of cardiovascular diseases attributable to metabolic risks across all age groups from 1990 to 2021: an analysis of the 2021 global burden of disease study data. BMC Public Health. 2025;25(1):1704. https://doi.org/10.1186/s12889-025-22702-7</Citation></Reference><Reference><Citation>Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219&#x2013;29. https://doi.org/10.1056/NEJMoa2025845 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2025845</ArticleId><ArticleId IdType="pubmed">33264825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252&#x2013;63. https://doi.org/10.1056/NEJMoa2110956 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110956</ArticleId><ArticleId IdType="pubmed">34449181</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475&#x2013;85. https://doi.org/10.1056/NEJMoa2407107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2407107</ArticleId><ArticleId IdType="pubmed">39225278</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, et al. Pharmacologic approaches to glycemic treatment: standards of care in diabetes&#x2014;2025. Diabetes Care. 2025;48(Supplement_1):S181&#x2013;206. https://doi.org/10.2337/dc25-S009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc25-S009</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020;76(9):1117&#x2013;45. https://doi.org/10.1016/j.jacc.2020.05.037 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.037</ArticleId><ArticleId IdType="pubmed">32771263</ArticleId><ArticleId IdType="pmc">7545583</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx N, Federici M, Sch&#xfc;tt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043&#x2013;140. https://doi.org/10.1093/eurheartj/ehad192 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad192</ArticleId><ArticleId IdType="pubmed">37622663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22(1):79. https://doi.org/10.1186/s12933-023-01798-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01798-4</ArticleId><ArticleId IdType="pubmed">37005640</ArticleId><ArticleId IdType="pmc">10067319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1&#x2013;127. https://doi.org/10.1016/j.kint.2022.06.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Navaneethan SD, Bansal N, Cavanaugh KL, et al. KDOQI US commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2025;85(2):135&#x2013;76. https://doi.org/10.1053/j.ajkd.2024.08.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2024.08.003</ArticleId><ArticleId IdType="pubmed">39556063</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/bmj.n71 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8479591</ArticleId></ArticleIdList></Reference><Reference><Citation>Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545&#x2013;57. https://doi.org/10.1016/S2213-8587(24)00155-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(24)00155-4</ArticleId><ArticleId IdType="pubmed">38991584</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossing P, Agarwal R, Anker SD, et al. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023;25(2):407&#x2013;16. https://doi.org/10.1111/dom.14883 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14883</ArticleId><ArticleId IdType="pubmed">36193847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossing P, Anker SD, Filippatos G, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 2022;45(12):2991&#x2013;8. https://doi.org/10.2337/dc22-0294 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-0294</ArticleId><ArticleId IdType="pubmed">35972218</ArticleId><ArticleId IdType="pmc">9862372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Claggett BL, Kulac IJ, et al. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation. 2025;151(2):149&#x2013;58. https://doi.org/10.1161/CIRCULATIONAHA.124.072055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.072055</ArticleId><ArticleId IdType="pubmed">39340828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J, Savovi&#x107; J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Published online 2019.</Citation></Reference><Reference><Citation>Wells G, Shea B, O&#x2019;Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Published online 2021.</Citation></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010. https://doi.org/10.18637/jss.v036.i03 .</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer G, Carpenter JR, R&#xfc;cker G. Meta-analysis with R. London: Springer International Publishing; 2015. https://doi.org/10.1007/978-3-319-21416-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-21416-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Neves JS, Borges-Canha M, Vasques-N&#xf3;voa F, et al. GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. J Am Coll Cardiol. 2023;82(6):517&#x2013;25. https://doi.org/10.1016/j.jacc.2023.05.048 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.05.048</ArticleId><ArticleId IdType="pubmed">37532422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849&#x2013;56. https://doi.org/10.1038/s41591-024-03133-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03133-0</ArticleId><ArticleId IdType="pubmed">38914124</ArticleId><ArticleId IdType="pmc">11485243</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx N, Deanfield JE, Mann JFE, et al. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. 2025;151(23):1639&#x2013;50. https://doi.org/10.1161/CIRCULATIONAHA.125.074545 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.125.074545</ArticleId><ArticleId IdType="pubmed">40156843</ArticleId><ArticleId IdType="pmc">12144549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant Sodium-Glucose Cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145(8):565&#x2013;74. https://doi.org/10.1161/CIRCULATIONAHA.121.057934 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057934</ArticleId><ArticleId IdType="pubmed">34775781</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2501006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2501006</ArticleId><ArticleId IdType="pubmed">40802953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519&#x2013;29. https://doi.org/10.1016/S0140-6736(18)32261-X .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32261-X</ArticleId><ArticleId IdType="pubmed">30291013</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109&#x2013;21. https://doi.org/10.1056/NEJMoa2403347 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403347</ArticleId><ArticleId IdType="pubmed">38785209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896&#x2013;907. https://doi.org/10.1056/NEJMoa2108269 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108269</ArticleId><ArticleId IdType="pubmed">34215025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang MH, Wang HY, Kan WC, et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol Dial Transplant. 2025. https://doi.org/10.1093/ndt/gfaf064 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfaf064</ArticleId><ArticleId IdType="pubmed">40199739</ArticleId><ArticleId IdType="pmc">12477464</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Fan Z, Li Y, Xiao B, He C. Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: a propensity score-matched cohort study. Int J Cardiol. 2025;431: 133229. https://doi.org/10.1016/j.ijcard.2025.133229 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2025.133229</ArticleId><ArticleId IdType="pubmed">40187657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):177. https://doi.org/10.1186/s12933-025-02737-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-025-02737-1</ArticleId><ArticleId IdType="pubmed">40275332</ArticleId><ArticleId IdType="pmc">12023599</ArticleId></ArticleIdList></Reference><Reference><Citation>Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024. https://doi.org/10.1136/bmj-2023-078242 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-078242</ArticleId><ArticleId IdType="pubmed">38663919</ArticleId><ArticleId IdType="pmc">11043905</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Wadid M, Makwana B, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors. JACC: Heart Fail. 2024;12(11):1814&#x2013;26. https://doi.org/10.1016/j.jchf.2024.07.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2024.07.006</ArticleId><ArticleId IdType="pubmed">39207323</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfella R, Prattichizzo F, Sardu C, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):10. https://doi.org/10.1186/s12933-023-02118-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-02118-6</ArticleId><ArticleId IdType="pubmed">38184582</ArticleId><ArticleId IdType="pmc">10771648</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhu J, Fang Y, Huang C, Liou H, Chen M, Tsai M. Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: real-world evidence. J Diabetes Investig. 2025;16(2):204&#x2013;14. https://doi.org/10.1111/jdi.14361 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.14361</ArticleId><ArticleId IdType="pubmed">39569871</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Vega D, Cinza-Sanjurjo S, Eiras S, Gonz&#xe1;lez-Juanatey JR. Combined sodium-glucose-transporters inhibitors and glucagon-like-peptide receptor agonist compared with monotherapy improves long-term survival: a real-world registry. Am J Med. 2024;137(8):761-769.e1. https://doi.org/10.1016/j.amjmed.2024.04.032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2024.04.032</ArticleId><ArticleId IdType="pubmed">38729592</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley DR, Essa H, Austin P, et al. All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(10):2897&#x2013;909. https://doi.org/10.1111/dom.15185 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15185</ArticleId><ArticleId IdType="pubmed">37385958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez PD, Bhatia K, Bohra C, Mahmood K, Baruch L, Eng C. Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure. Am J Cardiol. 2022;181:87&#x2013;93. https://doi.org/10.1016/j.amjcard.2022.07.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2022.07.012</ArticleId><ArticleId IdType="pubmed">35963825</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuen BL, Fletcher RA, Heath L, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation. 2024;150(22):1781&#x2013;90. https://doi.org/10.1161/CIRCULATIONAHA.124.071689 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.071689</ArticleId><ArticleId IdType="pubmed">39210781</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 838277. https://doi.org/10.3389/fphar.2022.838277 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.838277</ArticleId><ArticleId IdType="pubmed">35185588</ArticleId><ArticleId IdType="pmc">8854770</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2410659 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2410659</ArticleId><ArticleId IdType="pubmed">41020526</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128&#x2013;39. https://doi.org/10.1016/S2213-8587(18)30314-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(18)30314-0</ArticleId><ArticleId IdType="pubmed">30635226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758&#x2013;64. https://doi.org/10.1038/s41591-024-03264-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03264-4</ArticleId><ArticleId IdType="pubmed">39218030</ArticleId><ArticleId IdType="pmc">11645272</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorado Prevention Center. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) (CONFIRMATION). https://clinicaltrials.gov/study/NCT06024746</Citation></Reference><Reference><Citation>Lu CY. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract. 2009;63(5):691&#x2013;7. https://doi.org/10.1111/j.1742-1241.2009.02056.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-1241.2009.02056.x</ArticleId><ArticleId IdType="pubmed">19392919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaswami J, Bhalla V, De Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020. https://doi.org/10.1161/CIR.0000000000000920 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000920</ArticleId><ArticleId IdType="pubmed">33176463</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7): 3651. https://doi.org/10.3390/ijms23073651 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073651</ArticleId><ArticleId IdType="pubmed">35409011</ArticleId><ArticleId IdType="pmc">8998569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463&#x2013;74. https://doi.org/10.1038/s41569-023-00849-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-023-00849-3</ArticleId><ArticleId IdType="pubmed">36977782</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevella P, Ekinci EI, MacIsaac RJ. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists. Nephrology. 2024;29(8):457&#x2013;69. https://doi.org/10.1111/nep.14336 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.14336</ArticleId><ArticleId IdType="pubmed">39030739</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B, Bakbak E, Teoh H, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol-Heart Circ Physiol. 2024;326(5):H1159&#x2013;76. https://doi.org/10.1152/ajpheart.00574.2023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00574.2023</ArticleId><ArticleId IdType="pubmed">38426865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv R, Xu L, Che L, Liu S, Wang Y, Dong B. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front Endocrinol. 2023;14:1125693. https://doi.org/10.3389/fendo.2023.1125693 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1125693</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale C, Louren&#xe7;o IM, Jordan G, et al. Early combination therapy with SGLT2i and GLP -1 RA or dual GIP / GLP -1 RA in type 2 diabetes. Diabetes Obes Metab. 2025;27(2):468&#x2013;81. https://doi.org/10.1111/dom.16077 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.16077</ArticleId><ArticleId IdType="pubmed">39604324</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Awad AS, Abdel-Rahman EM. Nonsteroidal mineralocorticoid receptor antagonist (finerenone) in cardiorenal disease. J Clin Med. 2023;12(19): 6285. https://doi.org/10.3390/jcm12196285 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12196285</ArticleId><ArticleId IdType="pubmed">37834929</ArticleId><ArticleId IdType="pmc">10573495</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas TR, Ho B, Kang J, Kaplan B. Post hoc analyses: after the facts. Transplantation. 2015;99(1):17&#x2013;20. https://doi.org/10.1097/TP.0000000000000581 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000581</ArticleId><ArticleId IdType="pubmed">25525920</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.5 (Updated August 2024). Cochrane; 2024. https://www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Barrowman MA, Peek N, Lambie M, Martin GP, Sperrin M. How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies. BMC Med Res Methodol. 2019;19(1):166. https://doi.org/10.1186/s12874-019-0808-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-019-0808-7</ArticleId><ArticleId IdType="pubmed">31366331</ArticleId><ArticleId IdType="pmc">6668192</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41029336</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial.</ArticleTitle><Pagination><StartPage>371</StartPage><MedlinePgn>371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-025-02924-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits in randomised controlled trials (RCT). However, the controlled nature of RCTs and the selected trial populations limit their generalizability to real-world practice. Substantial methodological advances now enable robust estimation of absolute risks, risk differences, and continuous on-treatment effects, providing more clinically interpretable measures of SGLT2i effectiveness than previously possible with traditional models reliant on hazard ratios.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a target trial emulation using nationwide Danish registries to evaluate the real-world effectiveness of SGLT2i versus dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type 2 diabetes (T2D) and cardiovascular disease (CVD). Outcomes included major adverse cardiovascular events (MACE), heart failure hospitalizations, and all-cause mortality. Absolute risks and risk differences for three years of continuous treatment were estimated using longitudinal targeted minimum loss-based estimation, adjusting for baseline and time-varying confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 116,823 patients who redeemed SGLT2i or DPP4i for the first time, 13,524 met inclusion and exclusion criteria (SGLT2i: 6,025; DPP4i: 7,499). At three years, the risk of MACE was 11.5% for SGLT2i users versus 14.2% for DPP4i users (risk-difference: 2.8 percentage-points, 95% CI: 1.1-4.4%). Heart failure hospitalizations were lower by 5.1 percentage-points (95% CI: 4.3-6.0%), and all-cause mortality by 3.1 percentage-points (95% CI: 1.5-4.7%), all favoring SGLT2i. Notably, we also observed a risk reduction in stroke by 2.4 percentage-points (95% CI: 1.7-3.1%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates the real-world effectiveness of continuous SGLT2i treatment in reducing cardiovascular events in patients with T2D and CVD. The absolute benefit of SGLT2i was larger in a real world population than in the intention to treat estimate in clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yazdanfard</LastName><ForeName>Puriya Daniel W&#xfc;rtz</ForeName><Initials>PDW</Initials><AffiliationInfo><Affiliation>Department for Clinical and Translational Research, Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, 2730, Herlev, Denmark. puriya.daniel.wuertz.yazdanfard@regionh.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, North Zealand University Hospital, Hiller&#xf8;d, Denmark. puriya.daniel.wuertz.yazdanfard@regionh.dk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Kathrine Kold</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department for Clinical and Translational Research, Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, North Zealand University Hospital, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zareini</LastName><ForeName>Bochra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, North Zealand University Hospital, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen-Bjergaard</LastName><ForeName>Ulrik</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Endocrinology Section, Department of Endocrinology and Nephrology, North Zealand University Hospital, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohlendorff</LastName><ForeName>Johan Sebastian</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munch</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Mikkel Porsborg</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department for Clinical and Translational Research, Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, North Zealand University Hospital, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prehospital Center, Region Zealand, Naestved, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasselbalch</LastName><ForeName>Rasmus Bo</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasseleus</LastName><ForeName>Viktor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valabhji</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Chelsea and Westminster Hospital Campus, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Pratik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzinger</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mader</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerds</LastName><ForeName>Thomas Alexander</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torp-Pedersen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Clinical and Translational Research, Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, 2730, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, North Zealand University Hospital, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REDDIE consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Competing interests: Competing interests (none for authors if nothing is stated): CTP received study grants in the past 36 months from Bayer and Novo Nordisk. ML received payment to own company for education of diabetes by Boehringer Ingelheim, Novo Nordisk and Eli Lilly. UBP received lecture fees and personal payments by Abott, Novo Nordisk and Sanofi with the addition of EASD meeting support from the latter two. JKM is a member of advisory boards of Abbott Diabetes Care, Becton-Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Medtronic, myLife, Novo Nordisk A/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem, Viatris and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtrust, MSD, Novo Nordisk A/S, Roche Diabetes Care, Sanofi, Viatris and Ypsomed. She is a shareholder of decide Clinical Software GmbH and elyte Diagnostics and serves as CMO of elyte Diagnostics. KK has recieved consulting frees and payment as speaker from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta and Nestle Health Science. With the addition of grants from AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Sanofi, Servier, Oramed Pharmaceuticals, Roche, Daiichi-Sankyo, Applied Therapeutics. JV receives support/grants from &#x2018;The north west london NIHR applied research collaboration including other NIHR grants, EU Horizon / UKRI grant and CW+ the official charity of Chelsea Westminster hospital NHS foundation trust. Additionally, JV was International Advisor for the Ministry of Public Health in Qatar&#x2019;s &#x201c;Diabetes, Obesity and Atherosclerotic Cardiovascular Disease Strategy 2024 to 2030&#x201d;, for a 3-month period in 2024.PC has received personal fees from Medtronic, Insulet, Dexcom, Abbott, Vertex, Lilly, Novo Nordisk and Sanofi. He has received research support from Abbott, Dexcom, Medtronic, Sanofi and Novo Nordisk.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41029336</ArticleId><ArticleId IdType="doi">10.1186/s12933-025-02924-0</ArticleId><ArticleId IdType="pii">10.1186/s12933-025-02924-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Duenas JAC, Sanchez PN, Bonilla CE. Comparison of clinical outcomes among cancer patients treated in and out of clinical trials. BMC Cancer. 2023;23(1):786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-023-11305-3</ArticleId><ArticleId IdType="pubmed">37612602</ArticleId><ArticleId IdType="pmc">10463452</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanche P, Zareini B, Rasmussen PV. A hazard ratio above one does not necessarily mean higher risk, when using a time-dependent Cox model. Res Methods Med Health Sci. 2022;3(2):42&#x2013;8.</Citation></Reference><Reference><Citation>Wax Y, Galai N, Carey V, Simchen E. Cox regression models for intermediate events, with discharge from hospital as an example. Epidemiol Camb Mass. 1993;4(2):120&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-199303000-00007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA. The hazards of hazard ratios. Epidemiol Camb Mass. 2010;21(1):13&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c1ea43</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansournia MA, Etminan M, Danaei G, Kaufman JS, Collins G. Handling time varying confounding in observational research. BMJ. 2017;359:j4587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4587</ArticleId><ArticleId IdType="pubmed">29038130</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M, Schwab J, Gruber S, Blaser N, Schomaker M, van der Laan M. Targeted maximum likelihood Estimation for dynamic and static longitudinal marginal structural working models. J Causal Inference. 2014; 18(2):147&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jci-2013-0007</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 ;16(3):232&#x2013;42.</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Wang W, Leaf DE. Target trial emulation: A framework for causal inference from observational data. JAMA. 2022;328(24):2446&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.21383</ArticleId><ArticleId IdType="pubmed">36508210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber S, Lee H, Phillips R, Ho M, van der Laan M. Developing a Targeted Learning-Based Statistical Analysis Plan. Stat Biopharm Res. 2023;15(3):468&#x2013;75.</Citation></Reference><Reference><Citation>Yazdanfard PD, S&#xf8;rensen KK, Consortium TR, Torp-Pedersen C. Statistical analysis plan: Emulation of a Target Trial in an EMPA-REG inspired population using the Danish registries. SGLT2i compared to DPP4i on Cardiovascular outcomes. 2024 July 10 [cited 2024 Dec 16]; Available from: https://doi.org/10.5281/zenodo.12705109</Citation></Reference><Reference><Citation>Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22&#x2013;5.</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S91125</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId><ArticleId IdType="pmc">4655913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kildemoes HW, S&#xf8;rensen HT, Hallas J. The Danish National prescription registry. Scand J Public Health. 2011;39(7 Suppl):38&#x2013;41.</Citation></Reference><Reference><Citation>Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26&#x2013;9.</Citation></Reference><Reference><Citation>Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7_suppl):103&#x2013;5.</Citation></Reference><Reference><Citation>Vm J, Aw R. Danish Education Registers. Scand J Public Health [Internet]. 2011 July [cited 2025 Jan 6];39(7 Suppl). Available from: https://pubmed.ncbi.nlm.nih.gov/21775362/</Citation></Reference><Reference><Citation>Arendt JFH, Hansen AT, Ladefoged SA, S&#xf8;rensen HT, Pedersen L, Adelborg K. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S245060</ArticleId><ArticleId IdType="pubmed">32547238</ArticleId><ArticleId IdType="pmc">7244445</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen ME, Kristensen JK, Reventlov Husted G, Cerqueira C, Rossing P. The Danish adult diabetes registry. Clin Epidemiol. 2016;8:429&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S99518</ArticleId><ArticleId IdType="pubmed">27843339</ArticleId><ArticleId IdType="pmc">5098513</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan MJ, Gruber S. Targeted minimum loss based Estimation of causal effects of multiple time point interventions. Int J Biostat. 2012;8(1).</Citation></Reference><Reference><Citation>Lam H. A Cheap Bootstrap Method for Fast Inference [Internet]. arXiv; 2022 [cited 2024 Dec 16]. Available from: http://arxiv.org/abs/2202.00090</Citation></Reference><Reference><Citation>Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry. Pharmacol Res. 2023;187:106597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106597</ArticleId><ArticleId IdType="pubmed">36470546</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolisso P, Belmonte M, Gallinoro E, Scarsini R, Bergamaschi L, Portolan L, et al. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI). Cardiovasc Diabetol. 2024;23(1):420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-024-02504-8</ArticleId><ArticleId IdType="pubmed">39574095</ArticleId><ArticleId IdType="pmc">11583434</ArticleId></ArticleIdList></Reference><Reference><Citation>Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, R&#xf8;rth R, Madelaire C et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19(1):107.</Citation></Reference><Reference><Citation>Nystr&#xf6;m T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):831&#x2013;41.</Citation></Reference><Reference><Citation>Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, J&#xf8;rgensen ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP&#x2013;4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606&#x2013;15.</Citation></Reference><Reference><Citation>Pasternak B, Ueda P, Eliasson B, Svensson AM, Franz&#xe9;n S, Gudbj&#xf6;rnsdottir S, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019;366:l4772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4772</ArticleId><ArticleId IdType="pubmed">31467044</ArticleId><ArticleId IdType="pmc">6713906</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang HY, Kim IW, Oh JM. Using real-world data for supporting regulatory decision making: comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data. Front Pharmacol. 2022;13:928121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.928121</ArticleId><ArticleId IdType="pubmed">36110539</ArticleId><ArticleId IdType="pmc">9468970</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero-Calafell J, Bur&#xf3;n A, Castells X, Porta M. Intention to treat and per protocol analyses: differences and similarities. J Clin Epidemiol [Internet]. 2024 Sept 1 [cited 2024 Dec 16];173. Available from: https://www.jclinepi.com/article/S0895&#x2013;4356%2824%2900213&#x2013;0/fulltext?utm_source=chatgpt.com</Citation></Reference><Reference><Citation>Mo Y, Lim C, Watson JA, White NJ, Cooper BS. Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ. 2020 July 1;m2215.</Citation></Reference><Reference><Citation>Pitkala KH, Strandberg TE. Clinical trials in older people. Age Ageing. 2022;51(5):afab282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afab282</ArticleId><ArticleId IdType="pubmed">35526845</ArticleId><ArticleId IdType="pmc">9080968</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.18269</ArticleId><ArticleId IdType="pubmed">30418475</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;13(24):2295&#x2013;306.</Citation></Reference><Reference><Citation>White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1305889</ArticleId><ArticleId IdType="pubmed">23992602</ArticleId></ArticleIdList></Reference><Reference><Citation>Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1307684</ArticleId><ArticleId IdType="pubmed">23992601</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, et al. Cardiovascular outcomes with sodium&#x2013;glucose cotransporter&#x2013;2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;31(1):159.</Citation></Reference><Reference><Citation>Armillotta M, Angeli F, Paolisso P, Belmonte M, Raschi E, Di Dalmazi G, et al. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. Pharmacol Ther. 2025;1:270:108861.</Citation></Reference><Reference><Citation>Fedele D, Casuso Alvarez M, Maida A, Vasumini N, Amicone S, Canton L, et al. Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials. Eur Heart J - Cardiovasc Pharmacother. 2025;11(5):441&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaf040</ArticleId><ArticleId IdType="pubmed">40464647</ArticleId><ArticleId IdType="pmc">12342982</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan MJ, Rose S. Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies [Internet]. Springer International Publishing; 2018. (Springer Series in Statistics). Available from: https://books.google.dk/books?id=vKFTDwAAQBAJ</Citation></Reference><Reference><Citation>Hernan MA, Robins JM. Causal Inference: What If [Internet]. CRC Press;, Chapman. &amp; Hall/CRC Monographs on Statistics &amp; Applied Probab). Available from: https://books.google.dk/books?id=_KnHIAAACAAJ</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>